Multidrug-resistant tuberculosis:
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Dordrecht [u.a.]
Kluwer
2000
|
| Schriftenreihe: | Resurgent and emerging infectious diseases
1 |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | XV, 312 S. graph. Darst. |
| ISBN: | 0792361695 |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV013364965 | ||
| 003 | DE-604 | ||
| 005 | 20001116 | ||
| 007 | t | ||
| 008 | 000928s2000 d||| |||| 00||| eng d | ||
| 020 | |a 0792361695 |9 0-7923-6169-5 | ||
| 035 | |a (OCoLC)43650735 | ||
| 035 | |a (DE-599)BVBBV013364965 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 050 | 0 | |a RC311.1 | |
| 082 | 0 | |a 616.9/95 |2 21 | |
| 084 | |a YE 1600 |0 (DE-625)153370:12905 |2 rvk | ||
| 245 | 1 | 0 | |a Multidrug-resistant tuberculosis |c ed. by Ivan Bastian ... |
| 246 | 1 | 3 | |a Multidrug resistant tuberculosis |
| 264 | 1 | |a Dordrecht [u.a.] |b Kluwer |c 2000 | |
| 300 | |a XV, 312 S. |b graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Resurgent and emerging infectious diseases |v 1 | |
| 650 | 4 | |a Résistance aux médicaments | |
| 650 | 4 | |a Résistance multiple aux médicaments | |
| 650 | 4 | |a Tuberculose | |
| 650 | 4 | |a Multidrug-resistant tuberculosis | |
| 650 | 4 | |a Tuberculosis, Multidrug-Resistant | |
| 650 | 0 | 7 | |a Tuberkulose |0 (DE-588)4130621-1 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Arzneimittelresistenz |0 (DE-588)4143180-7 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Tuberkulose |0 (DE-588)4130621-1 |D s |
| 689 | 0 | 1 | |a Arzneimittelresistenz |0 (DE-588)4143180-7 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Bastian, Ivan |e Sonstige |4 oth | |
| 830 | 0 | |a Resurgent and emerging infectious diseases |v 1 |w (DE-604)BV013438957 |9 1 | |
| 856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=009116234&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-009116234 | ||
Datensatz im Suchindex
| _version_ | 1804128142825095168 |
|---|---|
| adam_text | Table of Contents
Chapter 1 Introduction 1
/. Bastian and F. Portaels
1. Historical perspective 1
2. The Definition of MRTB 4
2.1 Rationale for the current definition of MDRTB 5
2.2 Importance of a strict definition for MDRTB 6
3. Virulence and other questions about MDRTB 7
4. MDRTB in the present and future 9
5. The perfect expression of our imperfect civilization 11
References 12
Chapter 2 The epidemiology of multidrug resistant tuberculosis 17
in the United States and other established market
economies
M. Moore, E. McCray and I. M. Onorato
1. Introduction 17
2. Emergence of MDRTB in the United States 18
3. Trends in TB in the United States, 1992 1998 19
4. MDRTB in the United States, 1993 1998 21
5. MDRTB in other established market economies 24
6. Lessons learned 24
References 26
Chapter 3 Epidemiology of multidrug resistant tuberculosis in 29
low and middle income countries
M. A. Espinal
1. Introduction 29
2. Transmission dynamics of MDRTB 30
3. Assessment of MDRTB prevalcence 32
4. Magnitude of MDRTB problem 33
4.1 Africa 33
4.2 Latin America 35
4.3 Asia 36
4.4 Eastern Europe 37
5. Concluding remarks 40
Acknowledgments 40
References 40
viii
Chapter 4 The interaction of human immunodeficiency virus and 45
multidrug resistant Mycobacterium tuberculosis
E. McCray and I. M. Onorato
1. Introduction 45
2. Trends in MDRTB and HIV co infection, 46
and characteristics of MDRTB patients with HIV infection in the
United States, 1993 1997
3. Outbreaks of MDRTB involving HIV infected patients 48
4. Association of HIV and TB co infection with acquired 50
drug resistance
5. Summary and conclusions 52
References 52
Chapter 5 Clinical mismanagement and other factors producing 59
antituberculosis drug resistance
A. Pablos Mendez and K. Lessnau
1. The genesis of anti tuberculosis drug resistance 59
2. Clinical mismanagement producing drug resistance 61
2.1 Delayed diagnosis and isolation 62
2.2 Inappropriate drug regimens 63
2.2.1 Inadequate initial therapy 63
2.2.2 Premature cessation of treatment 64
2.2.3 Inappropriate treatment modifications when 65
complications arise
2.2.4 Adding a single drug to a failing regimen 65
2.2.5 Failure to adjust preventive therapy 65
2.3 Poor treatment adherence and incomplete follow up 66
3. Programmatic factors associated with drug resistance 67
3.1 Use of treatment regimens other than standardized 68
short course chemotherapy (SCC)
3.2 Failure to employ direct observation of treatment 68
3.3 Availability of antituberculosis drugs over the counter 69
and in fixed dose combinations
3.4 Failure to isolate MDRTB patients 70
4. Conclusions 70
References 71
ix
Chapter 6 The molecular mechanisms of drug resistance in 77
Mycobacterium tuberculosis
H. E. Takiff
1. Introduction 77
2. Isoniazid resistance 79
2.1 The catalase/peroxidase, KatG 79
2.2 InhA, KasA, and AcpM 80
2.3 OxyR and regulators of the peroxide response 82
3. Pyrazinamide 84
4. Ethambutol 86
5. Rifampicin 87
6. Streptomycin 90
7. Fluoroquinolones 92
8. Kanamycin and amikacin, viomycin and capreomycin 96
9. Cycloserine 98
10. Conclusion 99
Acknowledgments 100
References 100
Chapter 7 DOTS and multidrug resistant tuberculosis 115
M. C. Raviglione
1. Introduction 115
2. DOTS: Current Status of tuberculosis control 116
achievements world wide
3. The drug resistance situation world wide 118
4. Evidence that DOTS prevents MDRTB 119
5. Can MDRTB be eliminated as a public health 121
problem by DOTS?
6. Elimination of MDRTB 125
7. Adapting DOTS to high MDRTB burden settings: 127
research issues
8. Conclusion 128
Acknowledgments 129
References 129
Chapter 8 Conventional methods for antimicrobial susceptibility 133
testing of Mycobacterium tuberculosis
L. Heifets
1. Introduction 133
2. General principles of a drug susceptibility test 134
X
3. Drug susceptibility tests using egg based medium 135
3.1 The original proportion method (simplified variant) 135
3.2 The resistance ratio (RR) method 136
3.3 The absolute concentration method 137
4. Direct and indirect tests using 7H10/7H11 Agar 13 8
4.1 Original CDC version 138
4.2 Disc version of the proportion method 139
4.3 National Jewish modification of the proportion method 139
5. Indirect test in liquid medium (BACTEC® method) 139
6. Conclusions 141
References 142
Chapter 9 Novel rapid antimicrobial susceptibility tests for 145
Mycobacterium tuberculosis
J. C. Palomino
1. Introduction 145
2. Novel genotypic techniques 146
2.1 Automated DNA sequencing 146
2.2 PCR single strand conformation polymorphism 147
(PCR SSC)
2.3 PCR heteroduplex formation (PCR HDF) 147
2.4 Solid phase hybridization assay 148
2.5 Emerging new technologies for rapid detection 149
ofMDRTB
2.5.1 DNA microarrays 149
2.5.2 Reporter systems 149
2.5.3 Miscellaneous genotypic techniques 150
3. Novel phenotypic techniques 151
3.1 Myobacteria growth indicator tube (MGIT) 151
3.2 The PhaB assay 152
3.3 E test 152
3.4 Rapid metabolic tests 153
3.5 Microcolony detection method 154
3.6 Miscellaneous phenotypic procedures 154
4. Conclusions 155
References 156
Chapter 10 Pharmacology of the second line antituberculosis 163
drugs
C. A. Peloquin and B. Auclair
1. Introduction 163
2. Aminoglycosides and polypeptides 163
xi
3. Clofazimine 165
4. Cycloserine 166
5. Ethionamide 167
6. Fluoroquinolones 168
7. Para aminosalicylic acid 170
8. Other drugs 171
9. Therapeutic drug monitoring 172
10. Summary 172
References 172
Chapter 11 Treatment of multidrug resistant tuberculosis 175
M. D. Iseman and G. A. Huitt
1. Introduction 175
2. Inadequate treatment programs and acquired 176
drug resistance
3. Biologic mechanisms of resistance 176
4. Current epidemiology of resistance 177
5. Effects of drug resistance on treatment outcome 178
5.1 HIV negative immunocompetent patients 17 8
5.2 Patients with HIV infection/AIDS/Immunosuppression 179
6. Implications of multidrug resistance for initial therapy 179
7. Treatment of patients with multidrug resistant tuberculosis 180
7.1 Initiation of retreatment for MDRTB 181
7.2 Drugs used in retreatment regimens 182
7.3 Monitoring re treatment 183
7.4 The role of resectional surgery 184
7.5 What to do in cases of ultimate treatment failure? 185
8. Prevention of tuberculosis in the contacts of MDRTB 185
patients
9. Summary 186
References 187
Chapter 12 Treatment of multidrug resistant tuberculosis in 191
developing countries
J. Crofton and A. Van Deun
1. Introduction 191
2. Causes of MDRTB in developing countries 191
3. The extent of MDRTB in developing countries 192
4. Misdiagnosis of MDRTB 193
5. Particular problems in developing countries 193
6. Potential approaches to the problem 194
6.1 The individualised approach 194
6.2 The standardised approach 195
xii
7. Appropriate contexts for MDRTB treatment programmes 198
7.1 Countries with successful DOTS programmes and low 198
MDRTB rates
7.2 Countries with recently introduced, effective DOTS 199
programmes
7.3 The former Soviet Union 200
7.4 Countries with high MDRTB rates and no DOTS 200
programme
8. Surgery for MDRTB cases 201
9. Conclusions 201
References 201
Chapter 13 Treatment of outcome of multidrug resistant 205
tuberculosis
E. E. Telzak
1. Introduction 205
2. HIV negative patients 206
3. HIV positive patients 208
4. Recommendations for empiric treatment 209
5. Conclusion 210
References 210
Chapter 14 Chemoprophylaxis and BCG in contacts of multidrug 213
resistant tuberculosis
R. A. Stapledon, R. Lumb and I. S. him
1. Introduction 213
2. Prevention and control of tuberculosis 214
3. Chemoprophylaxis 214
3.1 Rationale 214
3.2 Treatment of drug susceptible TB infection 215
3.3 HIV and TB co infection 215
3.4 Chemoprophylaxis for drug resistant TB 216
3.5 Drug options 217
3.6 Limitations 218
4. Bacille Calmette Guerin 218
5. Summary 221
Acknowledgment 221
References 221
xiii
Chapter 15 Multidrug resistant tuberculosis and the health care 225
worker
D. M. Weinstock and K. A. Sepkowitz
1. Introduction 225
2. Outbreaks of nosocomial MDRTB involving 226
HCWs: what is known
3. Preventing active MDRTB among HCWs: BCG 230
versus TST screening and prophylactic therapy
4. Managing the HCW after exposure to MDRTB 232
5. Prophylaxis of the HCW exposed to MDRTB 232
6. Furloughing the HCW with active MDRTB 233
7. Addressing HCW concerns over MDRTB 234
8. Conclusions 235
References 235
Chapter 16 The development of new chemotherapeutics for 241
multidrug resistant tuberculosis
C. E. Barry
1. Introduction 241
2. The near end of the pipeline: semisynthetic derivatives 242
of rifamycin for the treatment of multidrug resistant
tuberculosis
3. Targeting latent organisms metronidazole and beyond 243
4. The trouble with prodrugs 244
5. The deep end of the dream pool; a new paradigm for 246
drug development
6. Conclusion 248
References 249
Chapter 17 Population dynamics and control of multidrug 253
resistant tuberculosis
C. Dye andB. G. Williams
1. Introduction 253
2. A mathematical model for MDR 254
3. Dynamics and control of MDR 258
4. Conclusions 264
Acknowledgements 266
References 266
xiv
Chapter 18 Administrative, engineering, and personal protective 269
measures for controlling Mycobacterium tuberculosis
C. Richards and W. R. Jarvis
1. Introduction 269
2. Health care facility risk assessment 270
3. Administrative measures 270
3.1 Infection control plan 271
3.2 Early identification and diagnosis 271
3.2.1 Specimen collection 272
3.2.2 Ambulatory settings 272
3.3 Patient isolation 274
3.4 Healthcare worker education and training 274
3.5 Health care worker counselling and screening 275
3.6 Cough induction 275
3.7 Discharge planning 275
3.8 Program evaluation 276
4. Engineering controls 276
4.1 Ventilation 276
4.1.1 Local exhaust ventilation 276
4.1.2 General ventilation 277
4.2 HEPA filtration 278
4.3 Ultraviolet germicidal irradiation 278
5. Personal respiratory protective devices 279
5.1 Respirator s performance criteria 279
5.2 Specific respirators 279
5.3 Effectiveness 279
6. Effectiveness and adoption of TB control practices 280
7. Costs of TB control practices 281
8. Special challenges in limited resource regions 282
and countries 282
9. Summary and conclusions 282
References 283
Chapter 19 Making DOTS Plus work 285
P. E. Farmer, S. S. Shin, J. Bayona, J. Y. Kim, J. J. Furin
and J. G. Brenner
1. Introduction 285
2. What is DOTS plus? 286
3. Political commitment 288
3.1 The additional costs of treating MDRTB 289
3.2 Strict control of second line drugs 289
3.3 Expansion of TB control initiatives 290
XV
4. The role of reference laboratories 290
4.1 Drug resistance surveillance 291
5. Procurement of second line antituberculous drugs 294
5.1 Inclusion of second line drugs on the WHO 295
Essential Drugs List
5.2 Pooled procurement of second line drugs 296
6. The importance of directly observed therapy 297
7. Evaluating DOTS plus efforts 298
8. Conclusions: from DOTS to DOTS plus and back again 301
References 302
Index 307
|
| any_adam_object | 1 |
| building | Verbundindex |
| bvnumber | BV013364965 |
| callnumber-first | R - Medicine |
| callnumber-label | RC311 |
| callnumber-raw | RC311.1 |
| callnumber-search | RC311.1 |
| callnumber-sort | RC 3311.1 |
| callnumber-subject | RC - Internal Medicine |
| classification_rvk | YE 1600 |
| ctrlnum | (OCoLC)43650735 (DE-599)BVBBV013364965 |
| dewey-full | 616.9/95 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.9/95 |
| dewey-search | 616.9/95 |
| dewey-sort | 3616.9 295 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01747nam a2200457 cb4500</leader><controlfield tag="001">BV013364965</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20001116 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">000928s2000 d||| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0792361695</subfield><subfield code="9">0-7923-6169-5</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)43650735</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV013364965</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC311.1</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.9/95</subfield><subfield code="2">21</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">YE 1600</subfield><subfield code="0">(DE-625)153370:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Multidrug-resistant tuberculosis</subfield><subfield code="c">ed. by Ivan Bastian ...</subfield></datafield><datafield tag="246" ind1="1" ind2="3"><subfield code="a">Multidrug resistant tuberculosis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Dordrecht [u.a.]</subfield><subfield code="b">Kluwer</subfield><subfield code="c">2000</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XV, 312 S.</subfield><subfield code="b">graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Resurgent and emerging infectious diseases</subfield><subfield code="v">1</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Résistance aux médicaments</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Résistance multiple aux médicaments</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Tuberculose</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Multidrug-resistant tuberculosis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Tuberculosis, Multidrug-Resistant</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Tuberkulose</subfield><subfield code="0">(DE-588)4130621-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittelresistenz</subfield><subfield code="0">(DE-588)4143180-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Tuberkulose</subfield><subfield code="0">(DE-588)4130621-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Arzneimittelresistenz</subfield><subfield code="0">(DE-588)4143180-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bastian, Ivan</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Resurgent and emerging infectious diseases</subfield><subfield code="v">1</subfield><subfield code="w">(DE-604)BV013438957</subfield><subfield code="9">1</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=009116234&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-009116234</subfield></datafield></record></collection> |
| id | DE-604.BV013364965 |
| illustrated | Illustrated |
| indexdate | 2024-07-09T18:44:33Z |
| institution | BVB |
| isbn | 0792361695 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-009116234 |
| oclc_num | 43650735 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | XV, 312 S. graph. Darst. |
| publishDate | 2000 |
| publishDateSearch | 2000 |
| publishDateSort | 2000 |
| publisher | Kluwer |
| record_format | marc |
| series | Resurgent and emerging infectious diseases |
| series2 | Resurgent and emerging infectious diseases |
| spelling | Multidrug-resistant tuberculosis ed. by Ivan Bastian ... Multidrug resistant tuberculosis Dordrecht [u.a.] Kluwer 2000 XV, 312 S. graph. Darst. txt rdacontent n rdamedia nc rdacarrier Resurgent and emerging infectious diseases 1 Résistance aux médicaments Résistance multiple aux médicaments Tuberculose Multidrug-resistant tuberculosis Tuberculosis, Multidrug-Resistant Tuberkulose (DE-588)4130621-1 gnd rswk-swf Arzneimittelresistenz (DE-588)4143180-7 gnd rswk-swf Tuberkulose (DE-588)4130621-1 s Arzneimittelresistenz (DE-588)4143180-7 s DE-604 Bastian, Ivan Sonstige oth Resurgent and emerging infectious diseases 1 (DE-604)BV013438957 1 HBZ Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=009116234&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Multidrug-resistant tuberculosis Resurgent and emerging infectious diseases Résistance aux médicaments Résistance multiple aux médicaments Tuberculose Multidrug-resistant tuberculosis Tuberculosis, Multidrug-Resistant Tuberkulose (DE-588)4130621-1 gnd Arzneimittelresistenz (DE-588)4143180-7 gnd |
| subject_GND | (DE-588)4130621-1 (DE-588)4143180-7 |
| title | Multidrug-resistant tuberculosis |
| title_alt | Multidrug resistant tuberculosis |
| title_auth | Multidrug-resistant tuberculosis |
| title_exact_search | Multidrug-resistant tuberculosis |
| title_full | Multidrug-resistant tuberculosis ed. by Ivan Bastian ... |
| title_fullStr | Multidrug-resistant tuberculosis ed. by Ivan Bastian ... |
| title_full_unstemmed | Multidrug-resistant tuberculosis ed. by Ivan Bastian ... |
| title_short | Multidrug-resistant tuberculosis |
| title_sort | multidrug resistant tuberculosis |
| topic | Résistance aux médicaments Résistance multiple aux médicaments Tuberculose Multidrug-resistant tuberculosis Tuberculosis, Multidrug-Resistant Tuberkulose (DE-588)4130621-1 gnd Arzneimittelresistenz (DE-588)4143180-7 gnd |
| topic_facet | Résistance aux médicaments Résistance multiple aux médicaments Tuberculose Multidrug-resistant tuberculosis Tuberculosis, Multidrug-Resistant Tuberkulose Arzneimittelresistenz |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=009116234&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV013438957 |
| work_keys_str_mv | AT bastianivan multidrugresistanttuberculosis |